Related Experiment Videos
[Bi-phenotypic leukemia and hybrid leukemia]
1First Department of Internal Medicine, Niigata University School of Medicine.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|June 1, 1992
Summary
Hybrid acute leukemia (HAL) involves leukemic cells with both lymphoid and myeloid markers. Identifying these phenotypes in acute leukemia patients can reveal high-risk groups needing tailored therapies.
Area of Science:
- Hematology
- Immunophenotyping
- Cancer Biology
Context:
- Accurate classification of acute leukemia is crucial for effective treatment.
- Laser flow cytometry with dual-color immunofluorescence enables detailed phenotyping of leukemic cells.
- Hybrid acute leukemia (HAL) presents a diagnostic challenge due to mixed lineage markers.
Purpose:
- To establish diagnostic criteria for Hybrid Acute Leukemia (HAL) using immunophenotyping.
- To classify HAL cases based on specific lymphoid and myeloid marker expression.
- To investigate the clinical implications of HAL phenotypes in adult acute leukemia patients.
Summary:
- A study defined HAL by the co-expression of ≥2 lymphoid markers and ≥1 myeloid marker on leukemic cells.
- Out of 111 untreated acute leukemia cases, 40 were diagnosed as HAL.
- HAL cases were categorized into four types based on CD33/CD13 and B-cell/T-cell antigen expression.
Impact:
- The findings suggest that HAL, particularly ALL cells expressing myeloid antigens (Types I and III), may represent a high-risk group in adults.
- This immunophenotypic classification aids in identifying acute lymphoblastic leukemia (ALL) patients with a poorer prognosis.
- Results highlight the importance of detailed immunophenotyping for risk stratification and personalized treatment strategies in acute leukemia.